Karim Lalji

Seattle, Washington, United States
Mr. Lalji began his career with Merck & Company where he led the infectious disease new product portfolio with responsibility for antibiotics and antivirals. He was a key member of the team that ultimately led to the discovery of the triple cocktail for treating HIV infections which revolutionized the management of HIV infection. Subsequent to Merck, Mr. Lalji worked at Sepracor, Inc. where he was Vice President of Business Strategy and New Product Commercialization. Mr. Lalji was the primary architect of LUNESTA for the treatment of insomnia at Sepracor. In 2006, Mr. Lalji joined Cardiome Pharma Corp. as the Chief Commercial Officer. He played a pivotal role in driving Cardiome’s $1 billion worldwide licensing agreement of a novel anti-arrhythmia therapy for the management of atrial fibrillation. Mr. Lalji holds a Science Masters Degree in Health Policy and Management from Harvard University in Cambridge, MA, and a BBA from Simon Fraser University in British Columbia, Canada.
Speaking In
[Available On-Demand]
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic…